Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients

Table 4 Adjusted hazard ratios for darunavir/ritonavir vs. atazanavir/ritonavir from sensitivity analyses

Analysis		Virologic Failure or Other Discontinuation		Virologic Failure		Discontinuations due to Virologic Failure		Other Discontinuation		Virologic Suppression
Analysis		aHR (95% CI)	p	aHR (95% CI)	p	aHR (95% CI)	p	aHR (95% CI)	p	aHR (95% CI)	p
0	Original Model	0.76 (0.56,1.03)	0.08	0.50 (0.28,0.91)	0.02	0.00 (0.00,0.00)	<.0001	0.93 (0.65,1.33)	0.68	0.99 (0.82,1.21)	0.96
1	Subgroup by Province
	ON/QC Only	0.73 (0.51,1.06)	0.10	0.90 (0.44,1.86)	0.78	0.00 (0.00,0.00)	<.0001	0.72 (0.47,1.11)	0.14	0.99 (0.78,1.27)	0.96
	BC Only	0.69 (0.34,1.42)	0.32	0.41 (0.09,1.78)	0.23	0.00 (0.00,0.00)	<.0001	0.93 (0.43,2.04)	0.86	0.78 (0.46,1.32)	0.35
2	Subgroup by Baseline VL
	< 100,000 copies/mL	0.66 (0.42,1.03)	0.07	0.47 (0.18,1.19)	0.11	0.00 (0.00,0.00)	<.0001	0.82 (0.49,1.36)	0.44	0.97 (0.76,1.23)	0.78
	≥ 100,000 copies/mL	0.86 (0.56,1.33)	0.49	0.54 (0.25,1.16)	0.11	0.00 (0.00,0.00)	<.0001	1.16 (0.68,2.00)	0.58	1.11 (0.81,1.53)	0.51
3	2010–2012 Only	0.81 (0.56,1.18)	0.27	0.55 (0.26,1.14)	0.11	0.00 (0.00,0.00)	<.0001	0.96 (0.63,1.48)	0.87	0.98 (0.76,1.26)	0.87
4	Simplification discontinuations included as competing risks	0.75 (0.54,1.03)	0.07	0.50 (0.28,0.91)	0.02	0.00 (0.00,0.00)	<.0001	0.92 (0.63,1.34)	0.65	0.99 (0.82,1.21)	0.96
5	SMC-FCS Imputation	0.76 (0.56, 1.04)	0.08	0.5 (0.28, 0.9)	0.02	0.00 (0.00,0.00)	<.0001	0.91 (0.62, 1.34)	0.64	0.98 (0.8, 1.2)	0.84

ISSN: 1471-2334